- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01567436
A Prospective Field Study: Introducing the Shang Ring in Routine Clinical Settings
A Prospective Study of Male Circumcision Using the Shang Ring in Routine Clinical Settings in Kenya & Zambia
Study Overview
Detailed Description
The World Health Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), and other global reproductive health organizations have recognized the highly protective effect of male circumcision to prevent HIV infection in men. Male Circumcision (MC) is the only new biomedical method to demonstrate consistent efficacy as an HIV prevention intervention in randomized controlled trials, based on three randomized controlled trials in Kenya, Uganda, and South Africa, that reported a protective effect of about 60%. Subsequent studies have confirmed the value and persistence of MC's protection against HIV infection, and have demonstrated that MC also reduces the transmission of human papillomavirus.
A wide variety of instruments, devices, and techniques are used around the world for male circumcision. The WHO, UNAIDS and JHPIEGO document entitled Manual for Male Circumcision under Local Anesthesia, includes step-by-step instructions for performing adult male circumcision using three different surgical procedures: the forceps-guided, dorsal slit, and sleeve resection methods. Procedure times for these techniques are approximately 20-30 minutes excluding anesthesia and involve control of unavoidable bleeding and a significant amount of suturing, and can be associated with complications that include hematoma formation, infection, unsatisfactory cosmetic result, lacerations of the penile or scrotal skin and injury to the glans, particularly among inexperienced surgeons. Although training is necessary regardless of method, devices for MC have the potential to reduce both training time and surgical duration because neither hemostasis nor suturing is needed for most devices.
The Shang Ring is an innovative device for adult male circumcision that has been on the Chinese market since 2005. The Shang Ring is manufactured by Wuhu SNNDA Medical Treatment Appliance Technology Co., Ltd (SNNDA).
In the current African setting, only surgical circumcision is available for adults. Devices such as the Shang Ring have the potential to simplify and shorten surgery by eliminating the need for suturing and hemostasis. Data from two small studies in Kenya suggest that the Shang Ring has an acceptable safety profile. A randomized controlled trial was conducted in Kenya and Zambia to provide further data.
Circumcision using the Shang Ring involves a few simple steps. First, a special measuring strip is used to determine which Shang Ring size to use. Following administration of local anesthesia, the inner ring is fitted at the base of the glans penis. Next, the foreskin is everted over the inner ring and the outer ring is secured (locked) over the inner ring, thus encasing the foreskin. The sterile device forms a tight seal. The foreskin is excised and several nicks are made in the foreskin on the underside of the device to prevent formation of a stiff, circumferential scab. Bleeding is minimal and no suturing or hemostasis is required. Finally, the participant returns in seven days for removal of the Shang Ring device. After removal, a bandage is applied to the wound. Men may be given a supply of bandages and told to change the bandaging daily or as needed.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All men enrolled in this research study must meet the following inclusion criteria:
- Must be aged 18 and 54 years;
- Must be uncircumcised (on examination);
- Must be in good general health;
- Must agree to HIV counseling and testing no more than one week before the procedure;
- Must be free of genital ulcerations or other visible signs of STI (on examination);
- Must be able to understand study procedures and requirements of study participation;
- Must agree to return to the healthcare facility for the full schedule of follow-up visits after his circumcision;
- Must freely consent to participate in the study and sign a written informed consent form;
- Must have a cell phone or access to a cell phone; and,
- Must agree to provide the study staff with an address, phone number, or other locator information while participating in the research study.
Exclusion Criteria:
A man will be excluded from participation in this research study if he has any of the following exclusion criteria:
- Has a known allergy or sensitivity to lidocaine or other local anesthesia;
- Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid;
- Has known bleeding/clotting disorder (e.g. hemophilia); or
- Has an active genital infection, anatomic abnormality or other condition (e.g. severe obesity, diabetes or sickle cell anemia), which in the opinion of the surgeon, prevents the man from undergoing a circumcision as part of this study;
- Is currently participating in another biomedical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: 42 days
|
42 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Acceptability of the Shang Ring Procedure
Time Frame: 42 days
|
42 days
|
Percentage of men completely healed at 42 days
Time Frame: 42 Days
|
42 Days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Marc Goldstein, M.D., Weill Cornell Medical College, NY, USA
- Study Chair: Mark A Barone, DVM, MS, EngenderHealth, NY, USA
- Principal Investigator: Philip S Li, MD, Weill Cornell Medical College, NY, USA
- Principal Investigator: Richard Lee, MD, Weill Cornell Medical College, NY, USA
- Principal Investigator: Paul Perchal, MA, EngenderHealth, NY, USA
- Principal Investigator: Jared Mogouche, MD ChB, EngenderHealth, Kisumu, Kenya
- Principal Investigator: Quentin Awori, MB ChB, EngenderHealth, Homa Bay, Kenya
- Principal Investigator: Raymond Simba, MB ChB MPH, Homa Bay District Hospital, Ministry of Health, Homa Bay, Kenya
- Principal Investigator: Nicholas Muraguri, MB ChB MPH, National AIDS/STD Control Programme, Nairobi, Kenya
- Principal Investigator: John M Wekesa, MB ChB MMed, Ministry of Medical Services, Nairobi, Kenya
- Principal Investigator: Kasonde Bowa, MSc M. Med FRCS FACS FCS, University of Zambia
- Principal Investigator: Robert Zulu, MD, University Teaching Hospital, Lusaka, Zambia
Publications and helpful links
General Publications
- Barone MA, Li PS, Zulu R, Awori QD, Agot K, Combes S, Simba RO, Lee RK, Hart C, Lai JJ, Zyambo Z, Goldstein M, Feldblum PJ, Sokal DC. Men's Understanding of and Experiences During the Postcircumcision Abstinence Period: Results From a Field Study of ShangRing Circumcision During Routine Clinical Services in Kenya and Zambia. J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1(Suppl 1):S18-23. doi: 10.1097/QAI.0000000000000704.
- Feldblum PJ, Okech J, Ochieng R, Hart C, Kiyuka G, Lai JJ, Veena V. Longer-Term Follow-Up of Kenyan Men Circumcised Using the ShangRing Device. PLoS One. 2015 Sep 14;10(9):e0137510. doi: 10.1371/journal.pone.0137510. eCollection 2015.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 10728
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Circumcision
-
ProgressusUnknownCircumcision, Male | Circumcision Status: Circumcised, Uncircumcised
-
University of North Carolina, Chapel HillBill and Melinda Gates Foundation; FHI 360; Impact Research & Development OrganizationCompletedVoluntary Medical Male Circumcision | Circumcision AdultKenya
-
Weill Medical College of Cornell UniversityBill and Melinda Gates FoundationCompleted
-
King Saud UniversityUnknownCircumcision, MaleSaudi Arabia
-
Medical University of South CarolinaCompleted
-
Simunye Primary Health CareCompleted
-
Kocatepe UniversityCompleted
-
ProgressusUnknownMale | CircumcisionZambia
-
Tehsil Headquarter HospitalCompleted
Clinical Trials on Shang Ring
-
FHI 360Cornell University; EngenderHealth; Kenya National AIDS & STI Control Programme; Ministry of Medical Services, KenyaCompletedMale CircumcisionKenya
-
Ningbo No. 1 HospitalThe Affiliated Hospital of Medical College, Ningbo UniversityCompletedHuman Immunodeficiency VirusChina
-
EngenderHealthWeill Medical College of Cornell University; Kenya Ministry of Health; Kenya...CompletedHuman Immunodeficiency VirusKenya
-
Weill Medical College of Cornell UniversityEngenderHealthCompletedHIV Infections | HIV Prevention | Male CircumcisionKenya
-
FHI 360Weill Medical College of Cornell University; EngenderHealth; University Teaching... and other collaboratorsCompleted
-
Mbarara University of Science and TechnologyCompleted
-
EngenderHealthWeill Medical College of Cornell University; Kenya Ministry of Health; Kenya... and other collaboratorsCompletedHuman Immunodeficiency VirusKenya
-
Chang Gung Memorial HospitalCompleted
-
Cairo UniversityNot yet recruiting
-
Clinica GastrobeseTerminatedVomiting | Gastroesophageal Reflux Disease | Morbid ObesityBrazil